UroGen Pharma Q2 EPS $(1.03) Beats $(1.14) Estimate, Sales $21.14M Beat $20.12M Estimate
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma reported Q2 earnings per share (EPS) of $(1.03), beating the analyst consensus estimate of $(1.14) by 9.65%. This is a 12.71% increase over losses from the same period last year. The company also reported quarterly sales of $21.14 million, beating the analyst consensus estimate of $20.12 million by 5.06%. This is a 27.31% increase over sales from the same period last year.
August 10, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma's Q2 earnings and sales beat analyst estimates, showing increases from the same period last year. This could potentially lead to a positive market reaction.
UroGen Pharma's better-than-expected Q2 results, both in terms of EPS and sales, could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100